Health

STAT+: Expert warns of battleground over global access to newer GLP-1 drugs for obesity

But there is another possibility: Obesity medications may become the next big battleground over access to medicines in lower-income countries, according to Ken Shadlen, a London School of Economics professor who studies the politics of pharmaceutical and health regulation.

✦ Extractive summary — built from the sources' own reporting•From 1 source•1 min read•Updated November 16, 2026, 6:18 PM UTC
Key points
  • Meanwhile, the pharmaceutical industry is racing to develop newer GLP-1 medicines that, to varying degrees, are forecast to be more effective, cause fewer side effects, and are easier to administer.
  • Continue to STAT+ to read the full story….
  • On one hand, these developments suggest more people than ever before may find needed help for losing weight.

You’re making a provocative point, although newer GLP-1 drugs that are better or easier to use or safer are not yet here.

Additional details
  • We spoke with him about the looming challenges that may soon confront drugmakers, governments, and patients.

How this summary was made: extractive summary — built from the sources' own reporting. It is drawn only from the reporting of the sources listed below — read the originals for full detail. How we summarize →

Advertisement

Every article behind this summary — 1 article from 1 outlet